Offentliggørelse af årsrapport 2022 samt endelige, reviderede udbytter for 2022, Investeringsforeningen Wealth Invest
Bestyrelsen for Investeringsforeningen Wealth Invest har på bestyrelsesmøde d.d. godkendt årsrapporten for 2022.
Årsrapporten er vedhæftet.
Derudover er de endelige, reviderede udbytter for 2022 blevet fastlagt i forbindelse med aflæggelse af årsrapporten. Disse kan findes i årsrapportens tabel 3 eller i tabellen nedenfor. Udbyttet vil blive indstillet til godkendelse af Foreningens generalforsamling den 19. april 2023.
| Afdeling/Andelsklasse | ISIN | Udbytte (kr. pr. andel) |
| AKL SEB Korte Obligationer I | DK0060567683 | 0,00 |
| AKL SEB Obligationer P | DK0060560670 | 0,00 |
| AKL SEB Obligationer I | DK0060567766 | 0,00 |
| AKL SEB Globale Aktier SRI I | DK0060813129 | 9,00 |
| AKL SEB Global High Yield Bonds SRI I | DK0060911998 | 0,00 |
| KK Obligationer | DK0061407509 | 0,00 |
| Linde & Partners Dividende Fond | DK0060660389 | 5,20 |
| Linde & Partners Dividende Fond I | DK0061151792 | 11,60 |
| AKL Lannebo Europa Small Cap P | DK0060908341 | 2,90 |
| AKL Lannebo Europa Small Cap I | DK0061031549 | 4,10 |
| Strategi Stabil | DK0060308583 | 0,00 |
| Strategi Aktier | DK0060308310 | 0,00 |
| Strategi Alternativer | DK0060885978 | 0,00 |
| AKL TimeInvest Sustainable Opportunities P | DK0061419199 | 0,00 |
| HP Invest Bolig | DK0061929205 | 0,00 |
| Secure Globale Obligationer | DK0060571446 | 1,40 |
| Secure Globale Aktier | DK0060571529 | 12,90 |
| Secure Select Aktier | DK0061553401 | 0,00 |
| Secure Market Power | DK0061148731 | 5,60 |
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Intervest Offices & Warehouses NV: Press release – Persbericht – Communiqué de presse: openbaarmaking over transparantiekennisgeving19.4.2024 18:00:00 CEST | Press release
Geachte mevrouw, meneer, Gelieve hierbij de links te vinden naar het recente persbericht van Intervest Offices & Warehouses betreffende de openbaarmaking over transparantiekennisgeving. Dear Madam, Sir, Please find hereunder the links to Intervest Offices & Warehouses’ latest press release regarding the publication of a transparency notification. Attachment NL_transparency notification_20240419
23/2024・Trifork Group AG – Shareholders approve all resolutions at the Annual General Meeting 202419.4.2024 17:34:19 CEST | Press release
Company announcement no. 23 / 2024 Schindellegi, Switzerland – 19 April 2024 Shareholders approve all resolutions at the Annual General Meeting 2024 The shareholders of Trifork Group AG (“Trifork“) today approved all resolutions proposed by the Board of Directors at Trifork’s Annual General Meeting 2024 (the “AGM“) which was held at Grabenstrasse 2, 6430 Baar, Switzerland. Dividend payment The shareholders approved the Board of Directors’ proposal to pay a gross dividend of EUR 0.10 per share (equivalent to CHF 0.10 per share) by making a payout from capital contribution reserves to the shareholders. The total gross dividend paid out amounts to CHFk 1,932, equivalent to DKKk 14,809, as calculated per the exchange rate published by the Swiss Federal Customs Administration as of 19 April 2024. The payout from capital contribution reserves is declared in CHF and paid out in DKK. Composition of the Board of Directors The shareholders re-elected Julie Galbo as Chairperson of the Board of Di
Havila Shipping ASA: Årsrapport 202319.4.2024 17:06:25 CEST | Pressemelding
Styret i Havila Shipping ASA har i dag godkjent regnskap og årsrapport for 2023 for konsern og morselskap. Resultatregnskap og balanser er i samsvar med foreløpig regnskap offentliggjort 27. februar 2024. Kontakter: Administrerende direktør Njål Sævik, +47 909 35 722 Finansdirektør Arne Johan Dale, +47 909 87 706 Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12 Vedlegg HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Havila Shipping ASA : Annual Report 202319.4.2024 17:06:25 CEST | Press release
Today, the Board of Directors of Havila Shipping ASA has approved the financial statements for 2023 for both the Group and the parent company. The accounts are in line with preliminary accounts released on 27 February 2024. Contacts: Chief Executive Officer Njål Sævik, +47 909 35 722 Chief Financial Officer Arne Johan Dale, +47 909 87 706 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act Attachments HAVI-20235967007LIEEXZXFJ8876-2023-12-31-no
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons19.4.2024 17:05:00 CEST | Press release
Company announcement – No. 23 / 2024 Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons Copenhagen, Denmark, April 19, 2024 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechnology company focused on the discovery and development of innovative peptide-based medicines, has received information on transactions in Zealand's shares or related securities conducted by persons discharging managerial responsibilities and/or their closely associated persons and hereby publishes the information on such transactions. Please see the attached file(s). # # # About Zealand Pharma A/S Zealand Pharma A/S (Nasdaq: ZEAL) ("Zealand") is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand have advanced into clinical development, of which two have reached the market and